This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Fasano M, Della Corte CM, Papaccio F, Ciardiello F, Morgillo F. Pulmonary Large-Cell Neuroendocrine Carcinoma: From Epidemiology to Therapy. J Thorac Oncol. 2015;10(8):1133–41.FasanoMDella CorteCMPapaccioFCiardielloFMorgilloFPulmonary Large-Cell Neuroendocrine Carcinoma: From Epidemiology to TherapyJ Thorac Oncol201510811334110.1097/JTO.0000000000000589450324626039012Search in Google Scholar
Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, et al. The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. J Thorac Oncol. 2015;10(9):1243–1260.TravisWDBrambillaENicholsonAGYatabeYAustinJHMBeasleyMBThe 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 ClassificationJ Thorac Oncol20151091243126010.1097/JTO.000000000000063026291008Search in Google Scholar
Hiroshima K, Mino-Kenudson M. Update on large cell neuroendocrine carcinoma. Transl Lung Cancer Res. 2017;6(5):530–539.HiroshimaKMino-KenudsonMUpdate on large cell neuroendocrine carcinomaTransl Lung Cancer Res20176553053910.21037/tlcr.2017.06.12565352729114469Search in Google Scholar
Rossi G, Cavazza A, Marchioni A, Longo L, Migaldi M, Sartori G, et al. Role of chemotherapy and the receptor tyrosine kinases KIT, PDGFRalpha, PDGFRbeta, and Met in large-cell neuroendocrine carcinoma of the lung. J Clin Oncol. 2005;23(34):8774–85.RossiGCavazzaAMarchioniALongoLMigaldiMSartoriGRole of chemotherapy and the receptor tyrosine kinases KIT, PDGFRalpha, PDGFRbeta, and Met in large-cell neuroendocrine carcinoma of the lungJ Clin Oncol2005233487748510.1200/JCO.2005.02.823316314638Search in Google Scholar
Hanna N, Johnson D, Temin S, Baker Jr S, Brahmer J, Ellis PM, et al. Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2017;35(30):3484–3515.HannaNJohnsonDTeminSBakerSJrBrahmerJEllisPMSystemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline UpdateJ Clin Oncol201735303484351510.1200/JCO.2017.74.606528806116Search in Google Scholar
Filosso PL, Guerrera F, Evangelista A, Galassi C, Welter S, Rendina EA, et al. Adjuvant chemotherapy for large-cell neuroendocrine lung carcinoma: results from the European Society for Thoracic Surgeons Lung Neuroendocrine Tumours Retrospective Database. Eur J Cardiothorac Surg. 2017;52(2):339–345.FilossoPLGuerreraFEvangelistaAGalassiCWelterSRendinaEAAdjuvant chemotherapy for large-cell neuroendocrine lung carcinoma: results from the European Society for Thoracic Surgeons Lung Neuroendocrine Tumours Retrospective DatabaseEur J Cardiothorac Surg201752233934510.1093/ejcts/ezx10128459956Search in Google Scholar
Varlotto JM, Medford-Davis LN, Recht A, Flickinger JC, Schaefer E, Zander DS, et al. Should large cell neuroendocrine lung carcinoma be classified and treated as a small cell lung cancer or with other large cell carcinomas? J Thorac Oncol. 2011;6(6):1050–8.VarlottoJMMedford-DavisLNRechtAFlickingerJCSchaeferEZanderDSShould large cell neuroendocrine lung carcinoma be classified and treated as a small cell lung cancer or with other large cell carcinomas?J Thorac Oncol2011661050810.1097/JTO.0b013e318217b6f821566535Search in Google Scholar
Derks JL, Hendriks LE, Buikhuisen WA, Groen HJ, Thunnissen E, van Suylen RJ, et al. Clinical features of large cell neuroendocrine carcinoma: a population-based overview. Eur Respir J. 2016;47(2):615–24.DerksJLHendriksLEBuikhuisenWAGroenHJThunnissenEvan SuylenRJClinical features of large cell neuroendocrine carcinoma: a population-based overviewEur Respir J20164726152410.1183/13993003.00618-201526541538Search in Google Scholar
Travis WD, Linnoila RI, Tsokos MG, Hitchcock CL, Cutler GB Jr, Nieman L, et al. Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases. Am J Surg Pathol. 1991;15(6):529–53.TravisWDLinnoilaRITsokosMGHitchcockCLCutlerGBJrNiemanLNeuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 casesAm J Surg Pathol19911565295310.1097/00000478-199106000-000031709558Search in Google Scholar
Asamura H, Kameya T, Matsuno Y, Noguchi M, Tada H, Ishikawa Y, et al. Neuroendocrine neoplasms of the lung: a prognostic spectrum. J Clin Oncol. 2006;24:70–6.AsamuraHKameyaTMatsunoYNoguchiMTadaHIshikawaYNeuroendocrine neoplasms of the lung: a prognostic spectrumJ Clin Oncol20062470610.1200/JCO.2005.04.120216382115Search in Google Scholar
Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. 4th ed. Lyon: IARC Press, 2015:63–8.TravisWDBrambillaEBurkeAPMarxANicholsonAGWHO Classification of Tumours of the Lung, Pleura, Thymus and Heart4th edLyonIARC Press2015638Search in Google Scholar
Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma: executive summary. J Thorac Oncol. 2011;6:244–285.TravisWDBrambillaENoguchiMNicholsonAGGeisingerKRYatabeYInternational Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma: executive summaryJ Thorac Oncol2011624428510.1097/JTO.0b013e318206a221451395321252716Search in Google Scholar
Tokito T, Kenmotsu H, Watanabe R, Ito I, Shukuya T, Ono A, et al. Comparison of chemotherapeutic efficacy between LCNEC diagnosed using large specimens and possible LCNEC diagnosed using small biopsy specimens. Int J Clin Oncol. 2014;19(1):63–7.TokitoTKenmotsuHWatanabeRItoIShukuyaTOnoAComparison of chemotherapeutic efficacy between LCNEC diagnosed using large specimens and possible LCNEC diagnosed using small biopsy specimensInt J Clin Oncol201419163710.1007/s10147-012-0509-223250620Search in Google Scholar
Oshiro Y, Kusumoto M, Matsuno Y, Asamura H, Tsuchiya R, Terasaki H, et al. CT findings of surgically resected large cell neuroendocrine carcinoma of the lung in 38 patients. AJR Am J Roentgenol. 2004;182(1):87–91.OshiroYKusumotoMMatsunoYAsamuraHTsuchiyaRTerasakiHCT findings of surgically resected large cell neuroendocrine carcinoma of the lung in 38 patientsAJR Am J Roentgenol20041821879110.2214/ajr.182.1.182008714684518Search in Google Scholar
Gazdar AF, Savage TK, Johnson JE, Berns A, Sage J, Linnoila RI, et al. The comparative pathology of genetically engineered mouse models for neuroendocrine carcinomas of the lung. J Thorac Oncol. 2015;10(4):553–64.GazdarAFSavageTKJohnsonJEBernsASageJLinnoilaRIThe comparative pathology of genetically engineered mouse models for neuroendocrine carcinomas of the lungJ Thorac Oncol20151045536410.1097/JTO.0000000000000459452322425675280Search in Google Scholar
Rindi G, Klersy C, Inzani F, Fellegara G, Ampollini L, Ardizzoni A, et al. Grading the neuroendocrine tumors of the lung: an evidence-based proposal. Endocr Relat Cancer. 2013;21(1):1–16.RindiGKlersyCInzaniFFellegaraGAmpolliniLArdizzoniAGrading the neuroendocrine tumors of the lung: an evidence-based proposalEndocr Relat Cancer201321111610.1530/ERC-13-024624344249Search in Google Scholar
Kinoshita T, Yoshida J, Ishii G, Aokage K, Hishida T, Nagai K. The differences of biological behavior based on the clinicopathological data between resectable large-cell neuroendocrine carcinoma and small-cell lung carcinoma. Clin Lung Cancer. 2013;14(5):535–40.KinoshitaTYoshidaJIshiiGAokageKHishidaTNagaiKThe differences of biological behavior based on the clinicopathological data between resectable large-cell neuroendocrine carcinoma and small-cell lung carcinomaClin Lung Cancer20131455354010.1016/j.cllc.2013.04.00323792008Search in Google Scholar
West HJ. Moving Beyond Limited and Extensive Staging of Small Cell Lung Cancer. JAMA Oncol. 2019;5(3):e185187.WestHJMoving Beyond Limited and Extensive Staging of Small Cell Lung CancerJAMA Oncol201953e18518710.1001/jamaoncol.2018.518730520935Search in Google Scholar
Eldessouki I, Gaber O, Namad T, Wang J, Morris JC, Abdel Karim N. Small or Non-Small Cell Lung Cancer Based Therapy for Treatment of Large Cell Neuroendocrine Cancer of The Lung? University of Cincinnati Experience. J Oncol. 2018;2018:9761826.EldessoukiIGaberONamadTWangJMorrisJCAbdel KarimNSmall or Non-Small Cell Lung Cancer Based Therapy for Treatment of Large Cell Neuroendocrine Cancer of The Lung? University of Cincinnati ExperienceJ Oncol20182018976182610.1155/2018/9761826623655730515212Search in Google Scholar
Rieber J, Schmitt J, Warth A, Muley T, Kappes J, Eichhorn F, et al. Outcome and prognostic factors of multimodal therapy for pulmonary large-cell neuroendocrine carcinomas. Eur J Med Res. 2015;20:64.RieberJSchmittJWarthAMuleyTKappesJEichhornFOutcome and prognostic factors of multimodal therapy for pulmonary large-cell neuroendocrine carcinomasEur J Med Res2015206410.1186/s40001-015-0158-9453669326272455Search in Google Scholar
Metro G, Ricciuti B, Chiari R, Baretti M, Falcinelli L, Giannarelli D, et al. Survival outcomes and incidence of brain recurrence in high-grade neuroendocrine carcinomas of the lung: Implications for clinical practice. Lung Cancer. 2016;95:82–7.MetroGRicciutiBChiariRBarettiMFalcinelliLGiannarelliDSurvival outcomes and incidence of brain recurrence in high-grade neuroendocrine carcinomas of the lung: Implications for clinical practiceLung Cancer20169582710.1016/j.lungcan.2016.03.00627040856Search in Google Scholar
Prelaj A, Rebuzzi SE, Del Bene G, Giròn Berrìos JR, Emiliani A, De Filippis L, et al. Evaluation of the efficacy of cisplatin-etoposide and the role of thoracic radiotherapy and prophylactic cranial irradiation in LCNEC. ERJ Open Res. 2017;3(1). pii: 00128-2016.PrelajARebuzziSEDel BeneGGiròn BerrìosJREmilianiADe FilippisLEvaluation of the efficacy of cisplatin-etoposide and the role of thoracic radiotherapy and prophylactic cranial irradiation in LCNECERJ Open Res201731pii:00128-201610.1183/23120541.00128-2016537031628382303Search in Google Scholar
Iyoda A, Hiroshima K, Moriya Y, Iwadate Y, Takiguchi Y, Uno T, et al. Postoperative recurrence and the role of adjuvant chemotherapy in patients with pulmonary large-cell neuroendocrine carcinoma. J Thorac Cardiovasc Surg. 2009;138(2):446–53.IyodaAHiroshimaKMoriyaYIwadateYTakiguchiYUnoTPostoperative recurrence and the role of adjuvant chemotherapy in patients with pulmonary large-cell neuroendocrine carcinomaJ Thorac Cardiovasc Surg200913824465310.1016/j.jtcvs.2008.12.03719619794Search in Google Scholar
Paci M, Cavazza A, Annessi V, Putrino I, Ferrari G, De Franco S, et al. Large cell neuroendocrine carcinoma of the lung: a 10-year clinicopathologic retrospective study. Ann Thorac Surg. 2004;77(4):1163–7.PaciMCavazzaAAnnessiVPutrinoIFerrariGDe FrancoSLarge cell neuroendocrine carcinoma of the lung: a 10-year clinicopathologic retrospective studyAnn Thorac Surg20047741163710.1016/j.athoracsur.2003.09.07015063227Search in Google Scholar
Veronesi G, Morandi U, Alloisio M, Terzi A, Cardillo G, Filosso P, et al. Large cell neuroendocrine carcinoma of the lung: a retrospective analysis of 144 surgical cases. Lung Cancer. 2006;53(1):111–5.VeronesiGMorandiUAlloisioMTerziACardilloGFilossoPLarge cell neuroendocrine carcinoma of the lung: a retrospective analysis of 144 surgical casesLung Cancer2006531111510.1016/j.lungcan.2006.03.00716697073Search in Google Scholar
Iyoda A, Hiroshima K, Moriya Y, Sekine Y, Shibuya K, Iizasa T, et al. Prognostic impact of large cell neuroendocrine histology in patients with pathologic stage Ia pulmonary non-small cell carcinoma. J Thorac Cardiovasc Surg. 2006;132(2):312–5.IyodaAHiroshimaKMoriyaYSekineYShibuyaKIizasaTPrognostic impact of large cell neuroendocrine histology in patients with pathologic stage Ia pulmonary non-small cell carcinomaJ Thorac Cardiovasc Surg20061322312510.1016/j.jtcvs.2006.02.04616872955Search in Google Scholar
Saji H, Tsuboi M, Matsubayashi J, Miyajima K, Shimada Y, Imai K, et al. Clinical response of large cell neuroendocrine carcinoma of the lung to perioperative adjuvant chemotherapy. Anticancer Drugs. 2010;21(1):89–93.SajiHTsuboiMMatsubayashiJMiyajimaKShimadaYImaiKClinical response of large cell neuroendocrine carcinoma of the lung to perioperative adjuvant chemotherapyAnticancer Drugs2010211899310.1097/CAD.0b013e328330fd7919770636Search in Google Scholar
Sarkaria IS, Iyoda A, Roh MS, Sica G, Kuk D, Sima CS, et al. Neoadjuvant and adjuvant chemotherapy in resected pulmonary large cell neuroendocrine carcinomas: a single institution experience. Ann Thorac Surg. 2011;92(4):1180–6.SarkariaISIyodaARohMSSicaGKukDSimaCSNeoadjuvant and adjuvant chemotherapy in resected pulmonary large cell neuroendocrine carcinomas: a single institution experienceAnn Thorac Surg20119241180610.1016/j.athoracsur.2011.05.02721867986Search in Google Scholar
Kim KW, Kim HK, Kim J, Shim YM, Ahn MJ, Choi YL. Outcomes of Curative-Intent Surgery and Adjuvant Treatment for Pulmonary Large Cell Neuroendocrine Carcinoma. World J Surg. 2017;41(7):1820–1827.KimKWKimHKKimJShimYMAhnMJChoiYLOutcomes of Curative-Intent Surgery and Adjuvant Treatment for Pulmonary Large Cell Neuroendocrine CarcinomaWorld J Surg20174171820182710.1007/s00268-017-3908-828204910Search in Google Scholar
Kujtan L, Muthukumar V, Kennedy KF, Davis JR, Masood A, Subramanian J. The Role of Systemic Therapy in the Management of Stage I Large Cell Neuroendocrine Carcinoma of the Lung. J Thorac Oncol. 2018;13(5):707–714.KujtanLMuthukumarVKennedyKFDavisJRMasoodASubramanianJThe Role of Systemic Therapy in the Management of Stage I Large Cell Neuroendocrine Carcinoma of the LungJ Thorac Oncol201813570771410.1016/j.jtho.2018.01.01929391287Search in Google Scholar
Iyoda A, Hiroshima K, Moriya Y, Takiguchi Y, Sekine Y, Shibuya K, et al. Prospective study of adjuvant chemotherapy for pulmonary large cell neuroendocrine carcinoma. Ann Thorac Surg. 2006;82(5):1802–7.IyodaAHiroshimaKMoriyaYTakiguchiYSekineYShibuyaKProspective study of adjuvant chemotherapy for pulmonary large cell neuroendocrine carcinomaAnn Thorac Surg20068251802710.1016/j.athoracsur.2006.05.10917062251Search in Google Scholar
Kenmotsu H, Niho S, Ito T, Ishikawa Y, Noguchi M, Tada H, et al. A pilot study of adjuvant chemotherapy with irinotecan and cisplatin for completely resected high-grade pulmonary neuroendocrine carcinoma (large cell neuroendocrine carcinoma and small cell lung cancer). Lung Cancer. 2014;84(3):254–8.KenmotsuHNihoSItoTIshikawaYNoguchiMTadaHA pilot study of adjuvant chemotherapy with irinotecan and cisplatin for completely resected high-grade pulmonary neuroendocrine carcinoma (large cell neuroendocrine carcinoma and small cell lung cancer)Lung Cancer2014843254810.1016/j.lungcan.2014.03.00724679951Search in Google Scholar
Eba J, Kenmotsu H, Tsuboi M, Niho S, Katayama H, Shibata T, et al. A Phase III trial comparing irinotecan and cisplatin with etoposide and cisplatin in adjuvant chemotherapy for completely resected pulmonary high-grade neuroendocrine carcinoma (JCOG1205/1206). Jpn J Clin Oncol. 2014;44(4):379–82.EbaJKenmotsuHTsuboiMNihoSKatayamaHShibataTA Phase III trial comparing irinotecan and cisplatin with etoposide and cisplatin in adjuvant chemotherapy for completely resected pulmonary high-grade neuroendocrine carcinoma (JCOG1205/1206)Jpn J Clin Oncol20144443798210.1093/jjco/hyt23324474818Search in Google Scholar
Filosso PL, Ruffini E, Oliaro A, Rena O, Casadio C, Mancuso M, et al. Large-cell neuroendocrine carcinoma of the lung: a clinicopathologic study of eighteen cases and the efficacy of adjuvant treatment with octreotide. J Thorac Cardiovasc Surg. 2005;129(4):819–24.FilossoPLRuffiniEOliaroARenaOCasadioCMancusoMLarge-cell neuroendocrine carcinoma of the lung: a clinicopathologic study of eighteen cases and the efficacy of adjuvant treatment with octreotideJ Thorac Cardiovasc Surg200512948192410.1016/j.jtcvs.2004.05.02315821649Search in Google Scholar
Sun JM, Ahn MJ, Ahn JS, Um SW, Kim H, Kim HK, et al. Chemotherapy for pulmonary large cell neuroendocrine carcinoma: similar to that for small cell lung cancer or non-small cell lung cancer? Lung Cancer. 2012;77(2):365–70.SunJMAhnMJAhnJSUmSWKimHKimHKChemotherapy for pulmonary large cell neuroendocrine carcinoma: similar to that for small cell lung cancer or non-small cell lung cancer?Lung Cancer20127723657010.1016/j.lungcan.2012.04.00922579297Search in Google Scholar
Naidoo J, Santos-Zabala ML, Iyriboz T, Woo KM, Sima CS, Fiore JJ, et al. Large Cell Neuroendocrine Carcinoma of the Lung: Clinico-Pathologic Features, Treatment, and Outcomes. Clin Lung Cancer. 2016;17(5):e121–e129.NaidooJSantos-ZabalaMLIyribozTWooKMSimaCSFioreJJLarge Cell Neuroendocrine Carcinoma of the Lung: Clinico-Pathologic Features, Treatment, and OutcomesClin Lung Cancer2016175e121e12910.1016/j.cllc.2016.01.003547431526898325Search in Google Scholar
Fujiwara Y, Sekine I, Tsuta K, Ohe Y, Kunitoh H, Yamamoto N, et al. Effect of platinum combined with irinotecan or paclitaxel against large cell neuroendocrine carcinoma of the lung. Jpn J Clin Oncol. 2007;37(7):482–6.FujiwaraYSekineITsutaKOheYKunitohHYamamotoNEffect of platinum combined with irinotecan or paclitaxel against large cell neuroendocrine carcinoma of the lungJpn J Clin Oncol2007377482610.1093/jjco/hym05317652109Search in Google Scholar
Le Treut J, Sault MC, Lena H, Souquet PJ, Vergnenegre A, Le Caer H, et al. Multicentre phase II study of cisplatin-etoposide chemotherapy for advanced large-cell neuroendocrine lung carcinoma: the GFPC 0302 study. Ann Oncol. 2013;24(6):1548–52.Le TreutJSaultMCLenaHSouquetPJVergnenegreALe CaerHMulticentre phase II study of cisplatin-etoposide chemotherapy for advanced large-cell neuroendocrine lung carcinoma: the GFPC 0302 studyAnn Oncol201324615485210.1093/annonc/mdt00923406729Search in Google Scholar
Niho S, Kenmotsu H, Sekine I, Ishii G, Ishikawa Y, Noguchi M, et al. Combination chemotherapy with irinotecan and cisplatin for large-cell neuroendocrine carcinoma of the lung: a multicenter phase II study. J Thorac Oncol. 2013;8(7):980–4.NihoSKenmotsuHSekineIIshiiGIshikawaYNoguchiMCombination chemotherapy with irinotecan and cisplatin for large-cell neuroendocrine carcinoma of the lung: a multicenter phase II studyJ Thorac Oncol201387980410.1097/JTO.0b013e31828f698923774385Search in Google Scholar
Derks JL, van Suylen RJ, Thunnissen E, den Bakker MA, Groen HJ, Smit EF, et al. Chemotherapy for pulmonary large cell neuroendocrine carcinomas: does the regimen matter? Eur Respir J. 2017;49(6). pii: 1601838.DerksJLvan SuylenRJThunnissenEden BakkerMAGroenHJSmitEFChemotherapy for pulmonary large cell neuroendocrine carcinomas: does the regimen matter?Eur Respir J2017496pii:160183810.1183/13993003.01838-2016589895128572122Search in Google Scholar
Monica V, Scagliotti GV, Ceppi P, Righi L, Cambieri A, Lo Iacono M, et al. Differential Thymidylate Synthase Expression in Different Variants of Large-Cell Carcinoma of the Lung. Clin Cancer Res. 2009;15(24):7547–7552.MonicaVScagliottiGVCeppiPRighiLCambieriALo IaconoMDifferential Thymidylate Synthase Expression in Different Variants of Large-Cell Carcinoma of the LungClin Cancer Res200915247547755210.1158/1078-0432.CCR-09-164119996214Search in Google Scholar
Sun JM, Han J, Ahn JS, Park K, Ahn MJ. Significance of thymidylate synthase and thyroid transcription factor 1 expression in patients with nonsquamous non-small cell lung cancer treated with pemetrexed-based chemotherapy. J Thorac Oncol. 2011;6(8):1392–9.SunJMHanJAhnJSParkKAhnMJSignificance of thymidylate synthase and thyroid transcription factor 1 expression in patients with nonsquamous non-small cell lung cancer treated with pemetrexed-based chemotherapyJ Thorac Oncol2011681392910.1097/JTO.0b013e3182208ea821716147Search in Google Scholar
Miyoshi T, Umemura S, Matsumura Y, Mimaki S, Tada S, Makinoshima H, et al. Genomic Profiling of Large-Cell Neuroendocrine Carcinoma of the Lung. Clin Cancer Res. 2017;23(3):757–765.MiyoshiTUmemuraSMatsumuraYMimakiSTadaSMakinoshimaHGenomic Profiling of Large-Cell Neuroendocrine Carcinoma of the LungClin Cancer Res201723375776510.1158/1078-0432.CCR-16-035527507618Search in Google Scholar
Christopoulos P, Engel-Riedel W, Grohé C, Kropf-Sanchen C, von Pawel J, Gütz S, et al. Everolimus with paclitaxel and carboplatin as first-line treatment for metastatic large-cell neuroendocrine lung carcinoma: a multicenter phase II trial. Ann Oncol. 2017;28(8):1898–1902.ChristopoulosPEngel-RiedelWGrohéCKropf-SanchenCvon PawelJGützSEverolimus with paclitaxel and carboplatin as first-line treatment for metastatic large-cell neuroendocrine lung carcinoma: a multicenter phase II trialAnn Oncol20172881898190210.1093/annonc/mdx26828535181Search in Google Scholar
Righi L, Volante M, Rapa I, Tavaglione V, Inzani F, Pelosi G, et al. Mammalian target of rapamycin signaling activation patterns in neuroendocrine tumors of the lung. Endocr Relat Cancer. 2010;17(4):977–87.RighiLVolanteMRapaITavaglioneVInzaniFPelosiGMammalian target of rapamycin signaling activation patterns in neuroendocrine tumors of the lungEndocr Relat Cancer20101749778710.1677/ERC-10-015720817788Search in Google Scholar
Alì G, Boldrini L, Capodanno A, Pelliccioni S, Servadio A, Crisman G, et al. Expression of p-AKT and p-mTOR in a large series of bronchopulmonary neuroendocrine tumors. Exp Ther Med. 2011;2(5):787–792.AlìGBoldriniLCapodannoAPelliccioniSServadioACrismanGExpression of p-AKT and p-mTOR in a large series of bronchopulmonary neuroendocrine tumorsExp Ther Med20112578779210.3892/etm.2011.291344072322977576Search in Google Scholar
Iyoda A, Travis WD, Sarkaria IS, Jiang SX, Amano H, Sato Y, et al. Expression profiling and identification of potential molecular targets for therapy in pulmonary large-cell neuroendocrine carcinoma. Exp Ther Med. 2011;2(6):1041–1045.IyodaATravisWDSarkariaISJiangSXAmanoHSatoYExpression profiling and identification of potential molecular targets for therapy in pulmonary large-cell neuroendocrine carcinomaExp Ther Med2011261041104510.3892/etm.2011.343344079322977617Search in Google Scholar
Nakamura H, Tsuta K, Yoshida A, Shibata T, Wakai S, Asamura H, et al. Aberrant anaplastic lymphoma kinase expression in high-grade pulmonary neuroendocrine carcinoma. J Clin Pathol. 2013;66(8):705–7.NakamuraHTsutaKYoshidaAShibataTWakaiSAsamuraHAberrant anaplastic lymphoma kinase expression in high-grade pulmonary neuroendocrine carcinomaJ Clin Pathol2013668705710.1136/jclinpath-2012-20132923618692Search in Google Scholar
Le X, Desai NV, Majid A, Karp RS, Huberman MS, Rangachari D, et al. De novo pulmonary small cell carcinomas and large cell neuroendocrine carcinomas harboring EGFR mutations: Lack of response to EGFR inhibitors. Lung Cancer. 2015;88(1):70–3.LeXDesaiNVMajidAKarpRSHubermanMSRangachariDDe novo pulmonary small cell carcinomas and large cell neuroendocrine carcinomas harboring EGFR mutations: Lack of response to EGFR inhibitorsLung Cancer201588170310.1016/j.lungcan.2015.02.003435531825700797Search in Google Scholar
Chae YK, Tamragouri KB, Chung J, Lin X, Miller V, Ali SM, et al. Large-Cell Neuroendocrine Carcinoma of the Lung: A Focused Analysis of BRAF Alterations and Case Report of a BRAF Non-V600–Mutated Tumor Responding to Targeted Therapy. JCO Precis Oncol. 2018;2:1–16.ChaeYKTamragouriKBChungJLinXMillerVAliSMLarge-Cell Neuroendocrine Carcinoma of the Lung: A Focused Analysis of BRAF Alterations and Case Report of a BRAF Non-V600–Mutated Tumor Responding to Targeted TherapyJCO Precis Oncol2018211610.1200/PO.17.0015035135105Search in Google Scholar
Zheng Q, Zheng M, Jin Y, Shen X, Shan L, Shen L, et al. ALK-rearrangement neuroendocrine carcinoma of the lung: a comprehensive study of a rare case series and review of literature. Onco Targets Ther. 2018;11:4991–4998.ZhengQZhengMJinYShenXShanLShenLALK-rearrangement neuroendocrine carcinoma of the lung: a comprehensive study of a rare case series and review of literatureOnco Targets Ther2018114991499810.2147/OTT.S172124610361230154667Search in Google Scholar
Hoton D, Humblet Y, Libbrecht L. Phenotypic variation of an ALK-positive large-cell neuroendocrine lung carcinoma with carcinoid morphology during treatment with ALK inhibitors. Histopathology. 2018;72(4):707–710.HotonDHumbletYLibbrechtLPhenotypic variation of an ALK-positive large-cell neuroendocrine lung carcinoma with carcinoid morphology during treatment with ALK inhibitorsHistopathology201872470771010.1111/his.1338828888040Search in Google Scholar
De Pas TM, Giovannini M, Manzotti M, Trifirò G, Toffalorio F, Catania C, et al. Large-cell neuroendocrine carcinoma of the lung harboring EGFR mutation and responding to gefitinib. J Clin Oncol. 2011;29(34):e819–22.De PasTMGiovanniniMManzottiMTrifiròGToffalorioFCataniaCLarge-cell neuroendocrine carcinoma of the lung harboring EGFR mutation and responding to gefitinibJ Clin Oncol20112934e8192210.1200/JCO.2011.36.225122042963Search in Google Scholar
Sakai Y, Yamasaki T, Kusakabe Y, Kasai D, Kotani Y, Nishimura Y, et al. Large-cell neuroendocrine carcinoma of lung with epidermal growth factor receptor (EGFR) gene mutation and co-expression of adenocarcinoma markers: a case report and review of the literature. Multidiscip Respir Med. 2013;8(1):47.SakaiYYamasakiTKusakabeYKasaiDKotaniYNishimuraYLarge-cell neuroendocrine carcinoma of lung with epidermal growth factor receptor (EGFR) gene mutation and co-expression of adenocarcinoma markers: a case report and review of the literatureMultidiscip Respir Med2013814710.1186/2049-6958-8-47372943923866929Search in Google Scholar
Tsoukalas N, Baxevanos P, Aravantinou-Fatorou E, Tolia M, Galanopoulos M, Tsapakidis K, et al. Advances on systemic treatment for lung neuroendocrine neoplasms. Ann Transl Med. 2018;6(8):146.TsoukalasNBaxevanosPAravantinou-FatorouEToliaMGalanopoulosMTsapakidisKAdvances on systemic treatment for lung neuroendocrine neoplasmsAnn Transl Med20186814610.21037/atm.2018.04.03595202129862235Search in Google Scholar
Fernandez-Cuesta L, Peifer M, Lu X, Seidel D, Zander T, Leenders F, et al. Cross-entity mutation analysis of lung neuroendocrine tumors sheds light into their molecular origin and identifies new therapeutic targets. Cancer Res. 2014;74(19 Suppl):1531.Fernandez-CuestaLPeiferMLuXSeidelDZanderTLeendersFCross-entity mutation analysis of lung neuroendocrine tumors sheds light into their molecular origin and identifies new therapeutic targetsCancer Res20147419 Suppl153110.1158/1538-7445.AM2014-1531Search in Google Scholar
Armengol G, Sarhadi VK, Rönty M, Tikkanen M, Knuuttila A, Knuutila S. Driver gene mutations of non-small-cell lung cancer are rare in primary carcinoids of the lung: NGS study by ion Torrent. Lung. 2015;193(2):303–8.ArmengolGSarhadiVKRöntyMTikkanenMKnuuttilaAKnuutilaSDriver gene mutations of non-small-cell lung cancer are rare in primary carcinoids of the lung: NGS study by ion TorrentLung20151932303810.1007/s00408-015-9690-125680416Search in Google Scholar
Vollbrecht C, Werner R, Walter RF, Christoph DC, Heukamp LC, Peifer M, et al. Mutational analysis of pulmonary tumours with neuroendocrine features using targeted massive parallel sequencing: a comparison of a neglected tumour group. Br J Cancer. 2015;113(12):1704–11.VollbrechtCWernerRWalterRFChristophDCHeukampLCPeiferMMutational analysis of pulmonary tumours with neuroendocrine features using targeted massive parallel sequencing: a comparison of a neglected tumour groupBr J Cancer20151131217041110.1038/bjc.2015.397470199426645239Search in Google Scholar
Karlsson A, Brunnström H, Lindquist KE, Jirström K, Jönsson M, Rosengren F, et al. Mutational and gene fusion analyses of primary large cell and large cell neuroendocrine lung cancer. Oncotarget. 2015;6(26):22028–37.KarlssonABrunnströmHLindquistKEJirströmKJönssonMRosengrenFMutational and gene fusion analyses of primary large cell and large cell neuroendocrine lung cancerOncotarget2015626220283710.18632/oncotarget.4314467314326124082Search in Google Scholar
Meder L, König K, Ozretić L, Schultheis AM, Ueckeroth F, Ade CP, et al. NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas. Int J Cancer. 2016;138(4):927–38.MederLKönigKOzretićLSchultheisAMUeckerothFAdeCPNOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomasInt J Cancer201613849273810.1002/ijc.29835483238626340530Search in Google Scholar
Rekhtman N, Pietanza MC, Hellmann MD, Naidoo J, Arora A, Won H, et al. Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-Small Cell Carcinoma-like Subsets [abstr]. Clin Cancer Res. 2016;22(14):3618–29.RekhtmanNPietanzaMCHellmannMDNaidooJAroraAWonHNext-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-Small Cell Carcinoma-like Subsets [abstr]Clin Cancer Res2016221436182910.1158/1078-0432.CCR-15-2946499577626960398Search in Google Scholar
Simbolo M, Mafficini A, Sikora KO, Fassan M, Barbi S, Corbo V, et al. Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatinremodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D. J Pathol. 2017;241(4):488–500.SimboloMMafficiniASikoraKOFassanMBarbiSCorboVLung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatinremodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2DJ Pathol2017241448850010.1002/path.4853Search in Google Scholar
George J, Walter V, Peifer M, Alexandrov LB, Seidel D, Leenders F, et al. Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors. Nat Commun. 2018;9(1):1048.GeorgeJWalterVPeiferMAlexandrovLBSeidelDLeendersFIntegrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumorsNat Commun201891104810.1038/s41467-018-03099-xSearch in Google Scholar
Derks JL, Leblay N, Lantuejoul S, Dingemans AC, Speel EM, Fernandez-Cuesta L. New Insights into the Molecular Characteristics of Pulmonary Carcinoids and Large Cell Neuroendocrine Carcinomas, and the Impact on Their Clinical Management. J Thorac Oncol. 2018;13(6):752–766.DerksJLLeblayNLantuejoulSDingemansACSpeelEMFernandez-CuestaLNew Insights into the Molecular Characteristics of Pulmonary Carcinoids and Large Cell Neuroendocrine Carcinomas, and the Impact on Their Clinical ManagementJ Thorac Oncol201813675276610.1016/j.jtho.2018.02.002Search in Google Scholar
Semenova EA, Kwon MC, Monkhorst K, Song JY, Bhaskaran R, Krijgsman O, et al. Transcription Factor NFIB Is a Driver of Small Cell Lung Cancer Progression in Mice and Marks Metastatic Disease in Patients. Cell Rep. 2016;16(3):631–43.SemenovaEAKwonMCMonkhorstKSongJYBhaskaranRKrijgsmanOTranscription Factor NFIB Is a Driver of Small Cell Lung Cancer Progression in Mice and Marks Metastatic Disease in PatientsCell Rep20161636314310.1016/j.celrep.2016.06.020Search in Google Scholar
Jones MH, Virtanen C, Honjoh D, Miyoshi T, Satoh Y, Okumura S, et al. Two prognostically significant subtypes of high-grade lung neuroendocrine tumours independent of small-cell and large-cell neuroendocrine carcinomas identified by gene expression profiles. Lancet. 2004;363(9411):775–81.JonesMHVirtanenCHonjohDMiyoshiTSatohYOkumuraSTwo prognostically significant subtypes of high-grade lung neuroendocrine tumours independent of small-cell and large-cell neuroendocrine carcinomas identified by gene expression profilesLancet200436394117758110.1016/S0140-6736(04)15693-6Search in Google Scholar
Shibata T, Kokubu A, Miyamoto M, Hosoda F, Gotoh M, Tsuta K, et al. DEK oncoprotein regulates transcriptional modifiers and sustains tumor initiation activity in high-grade neuroendocrine carcinoma of the lung. Oncogene. 2010;29(33):4671–81.ShibataTKokubuAMiyamotoMHosodaFGotohMTsutaKDEK oncoprotein regulates transcriptional modifiers and sustains tumor initiation activity in high-grade neuroendocrine carcinoma of the lungOncogene2010293346718110.1038/onc.2010.21720543864Search in Google Scholar
Chae YK, Tamragouri K, Chung J, Schrock AB, Kolla B, Ganesan S, et al. Genomic alterations (GA) and tumor mutational burden (TMB) in large cell neuroendocrine carcinoma of lung (L-LCNEC) as compared to small cell lung carcinoma (SCLC) as assessed via comprehensive genomic profiling (CGP) [abstr]. J Clin Oncol. 2017;35(suppl 15):8517.ChaeYKTamragouriKChungJSchrockABKollaBGanesanSGenomic alterations (GA) and tumor mutational burden (TMB) in large cell neuroendocrine carcinoma of lung (L-LCNEC) as compared to small cell lung carcinoma (SCLC) as assessed via comprehensive genomic profiling (CGP) [abstr]J Clin Oncol201735suppl 15851710.1200/JCO.2017.35.15_suppl.8517Search in Google Scholar
Tang M, Neda K, Ramineni M, Fujimoto J, Zhang J, Li J, et al. Histology determination of lung cancers: a report on genomic profiling of lung cancer of mixing histology [abstr]. J Clin Oncol. 2017;35 (suppl 15):8570.TangMNedaKRamineniMFujimotoJZhangJLiJHistology determination of lung cancers: a report on genomic profiling of lung cancer of mixing histology [abstr]J Clin Oncol201735suppl 15857010.1200/JCO.2017.35.15_suppl.8570Search in Google Scholar
Gazdar AF, Savage TK, Johnson JE, Berns A, Sage J, Linnoila RI, et al. The comparative pathology of genetically engineered mouse models for neuroendocrine carcinomas of the lung. J Thorac Oncol. 2015;10:553–564.GazdarAFSavageTKJohnsonJEBernsASageJLinnoilaRIThe comparative pathology of genetically engineered mouse models for neuroendocrine carcinomas of the lungJ Thorac Oncol20151055356410.1097/JTO.0000000000000459452322425675280Search in Google Scholar
Akeno N, Reece AL, Callahan M, Miller AL, Kim RG, He D, et al. TRP53 Mutants Drive Neuroendocrine Lung Cancer Through Loss-of-Function Mechanisms with Gain-of-Function Effects on Chemotherapy Response. Mol Cancer Ther. 2017;16(12):2913–2926.AkenoNReeceALCallahanMMillerALKimRGHeDTRP53 Mutants Drive Neuroendocrine Lung Cancer Through Loss-of-Function Mechanisms with Gain-of-Function Effects on Chemotherapy ResponseMol Cancer Ther201716122913292610.1158/1535-7163.MCT-17-0353571687528847987Search in Google Scholar
Derks JL, Leblay N, Thunnissen E, van Suylen RJ, den Bakker M, Groen HJM, et al. Molecular Subtypes of Pulmonary Large-cell Neuroendocrine Carcinoma Predict Chemotherapy Treatment Outcome. Clin Cancer Res. 2018;24(1):33–42.DerksJLLeblayNThunnissenEvan SuylenRJden BakkerMGroenHJMMolecular Subtypes of Pulmonary Large-cell Neuroendocrine Carcinoma Predict Chemotherapy Treatment OutcomeClin Cancer Res2018241334210.1158/1078-0432.CCR-17-192129066508Search in Google Scholar
Moris D, Ntanasis-Stathopoulos I, Tsilimigras DI, Adam MA, Yang C-FJ, Harpole D, et al. Insights into Novel Prognostic and Possible Predictive Biomarkers of Lung Neuroendocrine Tumors. Cancer Genomics Proteomics. 2018;15(2):153–163.MorisDNtanasis-StathopoulosITsilimigrasDIAdamMAYangC-FJHarpoleDInsights into Novel Prognostic and Possible Predictive Biomarkers of Lung Neuroendocrine TumorsCancer Genomics Proteomics2018152153163Search in Google Scholar
Ito T, Matsubara D, Tanaka I, Makiya K, Tanei ZI, Kumagai Y, et al. Loss of YAP1 defines neuroendocrine differentiation of lung tumors. Cancer Sci. 2016;107(10):1527–1538.ItoTMatsubaraDTanakaIMakiyaKTaneiZIKumagaiYLoss of YAP1 defines neuroendocrine differentiation of lung tumorsCancer Sci2016107101527153810.1111/cas.13013508467327418196Search in Google Scholar
Karlsson A, Brunnström H, Micke P, Veerla S, Mattsson J, La Fleur L, et al. Gene Expression Profiling of Large Cell Lung Cancer Links Transcriptional Phenotypes to the New Histological WHO 2015 Classification. J Thorac Oncol. 2017;12(8):1257–1267.KarlssonABrunnströmHMickePVeerlaSMattssonJLa FleurLGene Expression Profiling of Large Cell Lung Cancer Links Transcriptional Phenotypes to the New Histological WHO 2015 ClassificationJ Thorac Oncol20171281257126710.1016/j.jtho.2017.05.00828535939Search in Google Scholar
Aggarwal R, Mansfield A, Beltran H, Farago AF, Hann CL, Kaye F, et al. Preliminary Safety and Efficacy of Rovalpituzumab Tesirine in Patients With Delta-Like Protein 3-Expressing Advanced Solid Tumors [abstr]. Ann Oncol. 2017;28(suppl 5):145.AggarwalRMansfieldABeltranHFaragoAFHannCLKayeFPreliminary Safety and Efficacy of Rovalpituzumab Tesirine in Patients With Delta-Like Protein 3-Expressing Advanced Solid Tumors [abstr]Ann Oncol201728suppl 514510.1093/annonc/mdx368.008Search in Google Scholar
Saunders LR, Bankovich AJ, Anderson WC, Aujay MA, Bheddah S, Black K, et al. A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo. Sci Transl Med. 2015;7(302):302ra136.SaundersLRBankovichAJAndersonWCAujayMABheddahSBlackKA DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivoSci Transl Med20157302302ra13610.1126/scitranslmed.aac9459493437526311731Search in Google Scholar
Daniel DB, Rudin CM, Hart L, Spigel DR, Edelman MJ, Goldschmidt J, et al. Results of a randomized, placebo-controlled, phase 2 study of tarextumab (TRXT, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC). Ann Oncol. 2017;28(suppl 5):540.DanielDBRudinCMHartLSpigelDREdelmanMJGoldschmidtJResults of a randomized, placebo-controlled, phase 2 study of tarextumab (TRXT, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC)Ann Oncol201728suppl 554010.1093/annonc/mdx386.004Search in Google Scholar
Marchetti A, Felicioni L, Pelosi G, Del Grammastro M, Fumagalli C, Sciarrotta M, et al. Frequent mutations in the neurotrophic tyrosine receptor kinase gene family in large cell neuroendocrine carcinoma of the lung. Hum Mutat. 2008;29(5):609–16.MarchettiAFelicioniLPelosiGDel GrammastroMFumagalliCSciarrottaMFrequent mutations in the neurotrophic tyrosine receptor kinase gene family in large cell neuroendocrine carcinoma of the lungHum Mutat20082956091610.1002/humu.2070718293376Search in Google Scholar
Farago AF, Taylor MS, Doebele RC, Zhu VW, Kummar S, Spira AI, et al. Clinicopathologic Features of Non-Small-Cell Lung Cancer Harboring an NTRK Gene Fusion. JCO Precis Oncol. 2018;2:1–12.FaragoAFTaylorMSDoebeleRCZhuVWKummarSSpiraAIClinicopathologic Features of Non-Small-Cell Lung Cancer Harboring an NTRK Gene FusionJCO Precis Oncol2018211210.1200/PO.18.00037613205630215037Search in Google Scholar
Odate S, Nakamura K, Onishi H, Kojima M, Uchiyama A, Nakano K, et al. TrkB/BDNF signaling pathway is a potential therapeutic target for pulmonary large cell neuroendocrine carcinoma. Lung Cancer. 2013;79(3):205–14.OdateSNakamuraKOnishiHKojimaMUchiyamaANakanoKTrkB/BDNF signaling pathway is a potential therapeutic target for pulmonary large cell neuroendocrine carcinomaLung Cancer20137932051410.1016/j.lungcan.2012.12.00423312550Search in Google Scholar
Odate S, Onishi H, Nakamura K, Kojima M, Uchiyama A, Kato M, et al. Tropomyosin-related kinase B inhibitor has potential for tumor regression and relapse prevention in pulmonary large cell neuroendocrine carcinoma. Anticancer Res. 2013;33(9):3699–703.OdateSOnishiHNakamuraKKojimaMUchiyamaAKatoMTropomyosin-related kinase B inhibitor has potential for tumor regression and relapse prevention in pulmonary large cell neuroendocrine carcinomaAnticancer Res20133393699703Search in Google Scholar
Tatematsu T, Sasaki H, Shimizu S, Okuda K, Shitara M, Hikosaka Y, et al. Investigation of neurotrophic tyrosine kinase receptor 1 fusions and neurotrophic tyrosine kinase receptor family expression in non-small-cell lung cancer and sensitivity to AZD7451 in vitro. Mol Clin Oncol. 2014;2(5):725–730.TatematsuTSasakiHShimizuSOkudaKShitaraMHikosakaYInvestigation of neurotrophic tyrosine kinase receptor 1 fusions and neurotrophic tyrosine kinase receptor family expression in non-small-cell lung cancer and sensitivity to AZD7451 in vitroMol Clin Oncol20142572573010.3892/mco.2014.318410666225054037Search in Google Scholar
Atrafi F, Groen HJM, Byers LA, Garralda E, Lolkema MP, Sangha RS, et al. A Phase I Dose-Escalation Study of Veliparib Combined with Carboplatin and Etoposide in Patients with Extensive-Stage Small Cell Lung Cancer and Other Solid Tumors. Clin Cancer Res. 2019;25(2):496–505.AtrafiFGroenHJMByersLAGarraldaELolkemaMPSanghaRSA Phase I Dose-Escalation Study of Veliparib Combined with Carboplatin and Etoposide in Patients with Extensive-Stage Small Cell Lung Cancer and Other Solid TumorsClin Cancer Res201925249650510.1158/1078-0432.CCR-18-201430327308Search in Google Scholar
Owonikoko TK, Dahlberg SE, Sica GL, Wagner LI, Wade JL 3rd, Srkalovic G, et al. Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study. J Clin Oncol. 2019;37(3):222–229.OwonikokoTKDahlbergSESicaGLWagnerLIWadeJL3rdSrkalovicGRandomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 StudyJ Clin Oncol201937322222910.1200/JCO.18.00264633839430523756Search in Google Scholar
Kim HS, Han J-Y, Lee GK, Lee JH. PARP1 expression in high-grade neuroendocrine carcinoma of the lung. J Clin Oncol. 2018;36(suppl 15):e20562.KimHSHanJ-YLeeGKLeeJHPARP1 expression in high-grade neuroendocrine carcinoma of the lungJ Clin Oncol201836suppl 15e2056210.1200/JCO.2018.36.15_suppl.e20562Search in Google Scholar
Fan Y, Ma K, Wang C, Ning J, Hu Y, Dong D, et al. Prognostic value of PD-L1 and PD-1 expression in pulmonary neuroendocrine tumors. Onco Targets Ther. 2016;9:6075–6082.FanYMaKWangCNingJHuYDongDPrognostic value of PD-L1 and PD-1 expression in pulmonary neuroendocrine tumorsOnco Targets Ther201696075608210.2147/OTT.S115054506349127785054Search in Google Scholar
Karim NA, Sendilnathan A, Eldessouki I, Orr-Asman M, Xie C, Wang J, et al. Immune Checkpoint Markers in Lung Large Cell Neuroendocrine Carcinomas (L- LCNEC) [abstr]. J Thorac Oncol. 2017;12(11):S1583–S1584.KarimNASendilnathanAEldessoukiIOrr-AsmanMXieCWangJImmune Checkpoint Markers in Lung Large Cell Neuroendocrine Carcinomas (L- LCNEC) [abstr]J Thorac Oncol20171211S1583S158410.1016/j.jtho.2017.09.087Search in Google Scholar
Tsuruoka K, Horinouchi H, Goto Y, Kanda S, Fujiwara Y, Nokihara H, et al. PD-L1 expression in neuroendocrine tumors of the lung. Lung Cancer. 2017;108:115–120.TsuruokaKHorinouchiHGotoYKandaSFujiwaraYNokiharaHPD-L1 expression in neuroendocrine tumors of the lungLung Cancer201710811512010.1016/j.lungcan.2017.03.00628625622Search in Google Scholar
Arpin D, Charpentier M, Bernardi M, Boni A, Watkin E, Goubin-Versini I, et al. PD-L1 Expression Pattern in Large Cell Neuroendocrine Carcinoma of the Lung: The GFPC 03-2017 “EPNEC” Study [abstr]. J Thorac Oncol. 2018;13(10):S550.ArpinDCharpentierMBernardiMBoniAWatkinEGoubin-VersiniIPD-L1 Expression Pattern in Large Cell Neuroendocrine Carcinoma of the Lung: The GFPC 03-2017 “EPNEC” Study [abstr]J Thorac Oncol20181310S55010.1016/j.jtho.2018.08.778Search in Google Scholar
Ohtaki Y, Kaira K, Atsumi J, Nagashima T, Kawashima O, Ibe T, et al. Prognostic significance of PD-L1 expression and tumor infiltrating lymphocytes in large cell neuroendocrine carcinoma of lung. Am J Transl Res. 2018;10(10):3243–3253.OhtakiYKairaKAtsumiJNagashimaTKawashimaOIbeTPrognostic significance of PD-L1 expression and tumor infiltrating lymphocytes in large cell neuroendocrine carcinoma of lungAm J Transl Res2018101032433253Search in Google Scholar
Hermans BCM, Derks JL, Thunnissen E, van Suylen RJ, den Bakker MA, Groen HJM, et al. Prevalence and prognostic value of PD-L1 expression in molecular subtypes of metastatic large cell neuroendocrine carcinoma (LCNEC). Lung Cancer. 2019;130:179–186.HermansBCMDerksJLThunnissenEvan SuylenRJden BakkerMAGroenHJMPrevalence and prognostic value of PD-L1 expression in molecular subtypes of metastatic large cell neuroendocrine carcinoma (LCNEC)Lung Cancer201913017918610.1016/j.lungcan.2019.02.02230885341Search in Google Scholar
Inamura K, Yokouchi Y, Kobayashi M, Ninomiya H, Sakakibara R, Nishio M, et al. Relationship of tumor PD-L1 (CD274) expression with lower mortality in lung high-grade neuroendocrine tumor. Cancer Med. 2017;6(10):2347–2356.InamuraKYokouchiYKobayashiMNinomiyaHSakakibaraRNishioMRelationship of tumor PD-L1 (CD274) expression with lower mortality in lung high-grade neuroendocrine tumorCancer Med20176102347235610.1002/cam4.1172563359428925087Search in Google Scholar
Kim HS, Lee JH, Nam SJ, Ock CY, Moon JW, Yoo CW, et al. Association of PD-L1 Expression with Tumor-Infiltrating Immune Cells and Mutation Burden in High-Grade Neuroendocrine Carcinoma of the Lung. J Thorac Oncol. 2018;13(5):636–648.KimHSLeeJHNamSJOckCYMoonJWYooCWAssociation of PD-L1 Expression with Tumor-Infiltrating Immune Cells and Mutation Burden in High-Grade Neuroendocrine Carcinoma of the LungJ Thorac Oncol201813563664810.1016/j.jtho.2018.01.00829378266Search in Google Scholar
Sabari JK, Julian RA, Ni A, Halpenny D, Hellmann MD, Drilon AE, et al. Outcomes of advanced pulmonary large cell neuroendocrine carcinoma stratified by RB1 loss, SLFN11 expression, and tumor mutational burden [abstr]. J Clin Oncol. 2018;36(suppl 15):e20568.SabariJKJulianRANiAHalpennyDHellmannMDDrilonAEOutcomes of advanced pulmonary large cell neuroendocrine carcinoma stratified by RB1 loss, SLFN11 expression, and tumor mutational burden [abstr]J Clin Oncol201836suppl 15e2056810.1200/JCO.2018.36.15_suppl.e20568Search in Google Scholar
Chauhan A, Arnold SM, Kolesar J, Thomas HE, Evers M, Anthony L. Immune checkpoint inhibitors in large cell neuroendocrine carcinoma: current status. Oncotarget. 2018;9(18):14738–14740.ChauhanAArnoldSMKolesarJThomasHEEversMAnthonyLImmune checkpoint inhibitors in large cell neuroendocrine carcinoma: current statusOncotarget2018918147381474010.18632/oncotarget.24553586570329581877Search in Google Scholar
Levra MG, Mazieres J, Valette CA, Molinier O, Planchard D, Frappat V, et al. Efficacy of Immune Checkpoint Inhibitors in Large Cell Neuroendocrine Lung Cancer: Results from a French Retrospective Cohort [abstr]. J Thorac Oncol. 2017;12(1):S702–S703.LevraMGMazieresJValetteCAMolinierOPlanchardDFrappatVEfficacy of Immune Checkpoint Inhibitors in Large Cell Neuroendocrine Lung Cancer: Results from a French Retrospective Cohort [abstr]J Thorac Oncol2017121S702S70310.1016/j.jtho.2016.11.923Search in Google Scholar
